Regulation of epidermal keratinocytes by growth factors

Shirakata, Yuji

doi:10.1016/j.jdermsci.2010.05.002

Cited by 75 publications

(74 citation statements)

References 98 publications

(104 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These receptors can be broadly subdivided into two groups based on their ligand specificities: HER1 binds all EGF-family ligands except the neuregulins, whereas HER2, 3, and 4 bind the neuregulins in addition to other select EGF-family ligands. 15 HER1, 2, and 3, but not 4, are expressed by human KCs. 24 EGF, HB-EGF, TGF-a, epiregulin, and neuregulin signaling fosters KC migration.…”

Section: 21mentioning

confidence: 91%

“…The EGF family consists of several members, including EGF, transforming growth factor-a (TGF-a), heparin-binding EGF (HB-EGF), amphiregulin, betacellulin, biregulin, epiregulin, epigen, and several neuregulin isoforms. 15,22,23 Human KCs express TGF-a, HB-EGF, amphiregulin, betacellulin, and epiregulin. 15,24 These factors are synthesized as type I transmembrane proteins that are post-translationally processed into soluble factors by proteases, such as the disintegrin and metalloproteases (ADAMs), in a process known as ectodomain shedding, and they are then free to act as autocrine or paracrine growth factors.…”

Section: 21mentioning

confidence: 99%

“…15,22,23 Human KCs express TGF-a, HB-EGF, amphiregulin, betacellulin, and epiregulin. 15,24 These factors are synthesized as type I transmembrane proteins that are post-translationally processed into soluble factors by proteases, such as the disintegrin and metalloproteases (ADAMs), in a process known as ectodomain shedding, and they are then free to act as autocrine or paracrine growth factors. 25 The EGF-family ligands bind to a group of four homo-or heterodimeric RTKs: HER1 (commonly known as EGFR, ErbB-1), HER2 (Neu, ErbB-2), HER3 (ErbB-3), and HER4 (ErbB-4).…”

Section: 21mentioning

confidence: 99%

“…Growth factors have been shown to induce the migration of single cells or sheets of cells in monolayer cultures of KCs, or sheets of cells in the three-dimensional matrix of the wounded skin of animal models. 15,16 Of course, growth factors are not the sole influence on KC migration; the composition and remodeling of the ECM and extracellular space are also important for KC migration. 17 The roles of growth factors in KC biology have been extensively reviewed.…”

Section: Introductionmentioning

confidence: 99%

“…17 The roles of growth factors in KC biology have been extensively reviewed. 15,16,18,19 Our discussion will focus on growth factors that primarily induce KC migration (Table 1). Ach, acetylcholine; AGF, angiopoietin-related growth factor; FB, fibroblast; FGF, fibroblast growth factor; GM-CSF, granulocyte macrophage-colony stimulating factor; HB-EGF, heparin binding-epidermal growth factor; HGF, hepatocyte growth factor; HMGB1, high mobility group protein b1; HP, hepatocytes; IGF-1, insulin-like growth factor 1; IGF1R, IGF-1 receptor; IR, insulin receptor; KC, keratinocyte; LK, leukocyte; LRP, LDL receptor-related protein 1; ML, melanocyte; MP, macrophage; MS, mesenchymal cells; MSP, macrophage-stimulating protein; NA, not available; NK1R, neurokinin 1 receptor; PB, pancreatic b-cells; PL, platelet; PNS, peripheral nervous system cells; SP, substance P; TGF, transforming growth factor-a; VEGFR, VEGF RTK receptor; VIP, vasoactive intestinal peptide.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

The Roles of Growth Factors in Keratinocyte Migration

Seeger

Paller

2015

Advances in Wound Care

166

126

View full text Add to dashboard Cite

Section: 21mentioning

confidence: 91%

Section: 21mentioning

confidence: 99%

Section: 21mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The Roles of Growth Factors in Keratinocyte Migration

Seeger

Paller

2015

Advances in Wound Care

166

126

View full text Add to dashboard Cite

Acanthosis nigricans in achondroplasia

Smid

Modaff

Alade

et al. 2018

American J of Med Genetics Pt A

View full text Add to dashboard Cite

Acanthosis nigricans (AN) in those with achondroplasia has been reported occasionally in the literature previously. Other disorders arising from constitutive activation of FGFR3 also manifest AN at various frequencies. We assessed the prevalence of AN in a sequential series of 477 individuals with achondroplasia. Using a REDCap database, we collected and analyzed what other features or medical issues may co-occur with AN in those with achondroplasia. AN arises in approximately 10% of individuals with achondroplasia. It usually first appears in preadolescence or adolescence, is more likely in the non-White population and in those who are obese. It is not severe and generally will need no treatment. It is not associated with any evident risk for neither hyperinsulinemic states nor malignancy, and therefore, no special investigations are warranted when it is recognized.Thus, clinicians should not be surprised or concerned upon discovering this finding in those with achondroplasia. In addition, the mechanisms and genetic causes of AN are detailed. K E Y W O R D S acanthosis nigricans, achondroplasia, FGFR3, pleiotropy

show abstract

Brief Report: Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti–Interferon‐γ Antibody, in Patients With Discoid Lupus Erythematosus

Werth

Fiorentino

Sullivan

et al. 2017

Arthritis & Rheumatology

View full text Add to dashboard Cite

ObjectiveInterferon‐γ (IFNγ) is implicated in the pathogenesis of discoid lupus erythematosus (DLE). This study sought to evaluate a single dose of AMG 811, an anti‐IFNγ antibody, in patients with DLE.MethodsThe study was designed as a phase I randomized, double‐blind, placebo‐controlled crossover study of the pharmacodynamics, safety, and clinical efficacy of AMG 811 in patients with DLE. Patients received a single subcutaneous dose of AMG 811 (180 mg) or placebo. The patients in sequence 1 received AMG 811 followed by placebo, while those in sequence 2 received placebo followed by AMG 811. Pharmacodynamic end points included global transcriptional analyses of lesional and nonlesional skin, IFNγ blockade signature (IGBS) transcriptional scores in the skin and blood, keratinocyte IFNγ RNA scores, and serum levels of CXCL10 protein. Additional end points were efficacy outcome measures, including the Cutaneous Lupus Erythematosus Disease Area and Severity Index, and safety outcome measures.ResultsSixteen patients with DLE were enrolled in the study (9 in sequence 1 and 7 in sequence 2). AMG 811 treatment reduced the IGBS score (which was elevated in DLE patients at baseline) in both the blood and lesional skin. The keratinocyte IFNγ RNA score was not affected by administration of AMG 811. Serum CXCL10 protein levels (which were elevated in the blood of DLE patients) were reduced with AMG 811 treatment. The AMG 811 treatment was well tolerated but did not lead to statistically significant improvements in any of the efficacy outcome measures.ConclusionAMG 811 treatment led to changes in IFNγ‐associated biomarkers and was well tolerated, but no significant clinical benefit was observed in patients with DLE.

show abstract

Regulation of epidermal keratinocytes by growth factors

Cited by 75 publications

References 98 publications

The Roles of Growth Factors in Keratinocyte Migration

The Roles of Growth Factors in Keratinocyte Migration

Acanthosis nigricans in achondroplasia

Brief Report: Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti–Interferon‐γ Antibody, in Patients With Discoid Lupus Erythematosus

Contact Info

Product

Resources

About